#NewAseBioMember | “AseBio gives us access to key resources, and potential collaborations and boosts our visibility”

AseBio. What does your company's work bring to the table and what is its strength?

Ane Rodrigo. Asparia Glycomics provides knowledge and innovation in the field of glycan synthesis and analysis. This applies to very relevant areas of biomedicine and biotechnology and the pharmaceutical industry such as cancer, immunology, vaccine development, or biomarkers offering highly customized solutions to the challenges posed by glycomics. 
Our strengths are the advanced and innovative technology we apply, our team of top-level professional experts, our broad and solid experience and specialized knowledge, and our very customer-centric approach, we adapt to their needs

AseBio. What is AseBio for you?

Ane Rodrigo. AseBio for us is a very important support in our activity to establish new collaborations, opportunities to expand the market nationally and internationally, gain visibility and promotion, and networking thanks to the events it organizes and participates in. It is also a source of reliable and updated information on the sector, on new sources of funding, on attracting and retaining talent. In short, it is a solid platform for our growth and innovation development because it gives us access to key resources, and potential collaborations and boosts our visibility.

AseBio. When did you first hear about AseBio?

Ane Rodrigo. Personally, about 15 years ago, when I was studying for a degree in Biotechnology in León and, in addition, I have been a member of AseBio. In the business world, I don't really have a specific memory, it has always been there as part of the national biotechnology ecosystem and its work, and capabilities have always been positively valued.

AseBio. What do you expect from being part of an association like AseBio?

Ane Rodrigo. We hope to grow together with AseBio as a company within the sector, that AseBio serves us as a platform to gain visibility, that we can offer our services to more customers who discover the world of glycomics and how important it is in biomedicine or improve their current processes with us. We also want it to be a bidirectional relationship and that we can complement AseBio as a specialized and expert company in a complex market niche with a lot of added value. We will bring innovation, knowledge, experience, and a new network of contacts and businesses to nurture the biotechnological landscape. 

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Ane Rodrigo. The biggest challenges Asparia is facing - and, as a biotech company, the entire industry - are the high level of competition, the level of differentiation, and the need for continuous innovation. In addition, it is also necessary to access financial resources to make investments in innovation profitable. In our case, market adoption and how our services are valued and perceived is a major challenge. We invest a lot of resources to educating customers about the importance of glycomics and the added value of what we offer, and we believe that from Asebio, we will be able to respond to some of the challenges we face as a collective and as individual companies.